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The interchromosomal 14; 18 translocation occurs in ap-
proximately 70 -:- 80% of follicular lymJ:?homas and in a lower 
proportion of htgh-grade non-Hodgkm lymphomas of the 
lymph nodes. This translocation results in the fusion of the 
bcl-2 oncogene on chromosome 18 with immunoglobulin 
heavy chain genes on chromosome 14, and in the expression 
of higher amo~nts .of normal bc~-2 prot.ein. W. e studied bc!-2 
expression in blOpstes of 1 08 pattents wtth bemgn and mahg-
nant cutaneous lymphoproliferative diseases (B-cell lym-
phoma, primary cutaneous, 42; secondary cutaneous, 
21; primary cutaneous T-cell lymphoma, 21; B-cell 
pseudolymphoma, 24), using a monoclonal anti - bcl-2 anti-
body on paraffin-eI?bedded ~issue .sections. bcl-2 protein was 
detected immunolustochemtcally m 16 of 63 cases of cutane-
ous B-celilymphoma, whereas cutaneous T-cell lymphomas 
and B-cell pseudolymphomas were negative. The proportion 
of bcl-2 protein expression was significantly higher in sec-
ondary (11/21) than in primary cutaneous B-celilymphomas 
(5/42; X2 test, p < 0.001). Biopsies from 25 of these patients 
T he interchromosomal 14;18 translocation [t(14;18) (q32;q21)] brings part of the bcl-2 gene on chromo-some 18 into juxtaposition with the immunoglobulin heavy chain gene locus on chromosome 14 [1]. The coding region of the bcl-2 gene is left intact, and the 
transcript is translated into a normal but markedly increased bcl-2 
protein [2.3]. This translocation occurs in .more than two thirds?f 
follicular lymphomas and 10-40% of lugh-grade non-Hodgkm 
lymphoma (NHL) of the lymph nodes [4-1~]. In~mu~ohistol~gic 
studies using polyclonal and monoclonal antibodies raised agamst 
the bcl-2 protein revealed that cases of nodal NHL with the t(14;18) 
express high levels of bcl-2 protein [11,12]. In addition, bcl-2 protein 
expression could be demonstrated in cases of nodal NHL that lacked 
the t(14; 18) [11,13], as well as in normal T and B lymphocytes [11]. 
Thus, the translocation is not necessarily a prerequisite for expres-
sion of bcl-2 protein. 
To date. there are no reports on bcl-2 protein expression in cuta-
neous Iymphoproliferative disorders. Previous molecular studies of 
primary cutaneous B-cell lymphomas using Southern blot tech-
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(B-celllymphoma, 22; B-cell pseudolymphoma, three) were 
analyzed previously on the molecular level for the t(14;18), 
using polymerase chain reaction amplification of DNA ob-
tained from paraffin-embedded sections. In four of 11 cases of 
bcl-2 protein-positive B-cell lymphoma (primary, one; sec-
ondary, three) the t(14;18) was detected by polymerase chain 
reaction. All other cases ofB-celllymphoma, including seven 
cases where bcl-2 protein was detected by immunohistology, 
and B-cell pseudolymphoma were negative. These results 
demonstrate: 1) bcl-2 protein is expressed in a small portion of 
cutaneous B-celilymphomas; 2) bcl-2 protein expression is 
significantly more frequent in secondary than in primary 
cutaneous B-cell lymphoma; 3) only approximately one-
third of cases expressing the bcl-2 protein are characterized 
also by the t(14;18) . bcl-2 protein expression might indicate 
that the cutaneous manifestation of the lymphoma represents 
a secondary spread from a node-based lymphoma. Key words: 
cutaneous lymphoma/pseudolymphoma/14;18 tral1s1ocati0l1/ 
bcl-2 proteitt. ] Invest Dermato11 02:231-235, 1994 
niques for detection of the t(14;18) yielded negative results [14,15]. 
In this study, we analyzed the expression of bcl-2 protein in 108 
cases of cutaneous lymphomas and pseudolymphomas of both B-
and T-cell lineage. Twenty-five of these cases had been analyzed in 
a previous study by the highly sensitive polymerase chain reaction 
(peR) technique for the presence of the t(14;18) [16]. 
MATERIALS AND METHODS 
Patients One hundred-eight patients with cutaneous benign and mal.ig-
nant lymphoproliferative disorders were included in the study. Cases in-
cluded 63 B-celllymphomas (42 representing primary and 21 secondary skin 
involvement), 21 primary cutaneous T -cell lymphomas. and 24 B-cell fol-
licular pseudolymphomas (lymphocytoma cutis) (Table I). Diagnoses were 
based on clinical, histopathologic. immunohistochemical, and follow-up 
data. In all cases the lineage of neoplastic cells was determined by detailed 
immunohistochemical analysis on frozen or paraffin-embedded tissue sec-
tions. Cases with a doubtful phenotype were excluded. In most cases, more 
than one biopsy was available for histopathologic, immunohistochemical, 
and molecular analyses. Primary skin involvement was defined as the pres-
ence of cutaneous lymphoma without nodal and/or visceral involvement for 
at least 6 months after complete staging procedures were performed. Nodal 
lymphomas with secondary skin manifestations were classified as secondary 
cutaneous lymphomas. 
Histology Sections of fonnalin-fixed, paraffin-embedded biopsies were 
stained with hematoxylin and eosin. periodic acid Schiff, and Giemsa stain-
ings for routine histopathologic evaluation. Lymphomas were classified ac-
cording to the updated Kiel classification of malignant lymphomas [17). 
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Table I. bcl-2 Protein Expression as Assessed by Immunohistochemistry in 108 Cases of Primary and Secondary Cutaneous Lymphomas 
Updated Grades Number bcl-2 
Kiel Classification Working Formulation of Malignancy of Cases Protein 
Primary cutaneous B-cell lymphoma 
Lymphoplasmacytoid 
Centroblastic-centrocytic 
Centrocytic 
Centroblastic 
Immunoblastic 
Secondary cutaneous B-ceillymphoma 
Lymphoplasmacytoid 
Plasmacytic 
Centroblastic-centrocytic 
Centrocytic 
Centroblastic 
Immunoblastic 
Lymphoblastic 
Primary cutaneous T-cell lymphoma 
Mycosis fungoides 
Sezary's syndrome 
Pleomorphic 
Immunoblastic 
Large cell anaplastic (Ki 1 +) 
B-cell pseudo lymphoma 
Lymphocytoma cutis 
Small lymphocytic, plasmacytoid 
Follicular and diffuse 
Diffuse, small cleaved cell, and large cell 
Follicular, predominantly large cell, sclerosis 
and diffuse, large cell, non-cleaved cell 
Large cell, immunoblastic 
Small lymphocytic, plasmacytoid . 
Extramedullary plasmacytoma 
Follicular and diffuse 
Diffuse, small cleaved cell, and large cell 
Follicular, predominantly large cell, sclerosis 
and diffuse, large cell, non-cleaved cell 
Large ceU, immunoblastic 
Lymphoblastic 
Mycosis fungoides 
Large cell, immunoblastic 
Low 
Low 
Low 
High 
High 
Low 
Low 
Low 
Low 
High 
High 
High 
Low 
Low 
Low/high 
High 
High 
42 
4 
24 
4 
4 
6 
21 
1 
1 
5 
3 
3 
7 
1 
21 
11 
2 
5 
2 
1 
24 
5 
1 
2 
o 
1 
1 
11 
o 
1 
3 
2 
o 
4 
1 
o 
o 
o 
o 
o 
o 
o 
Pseudolymphomas were diagnosed according to criteria by Ked and Acker-
man [18J. 
antibodies. Second and third antibodies were by Dakopatts (Denmark). The 
monoclonal anti-bcl-2 protein antibody used in' this study was kindly pro-
vided by Dr. D.Y. Mason (Oxford, UK). Details on the production of this 
antibody were previously described [11]. Stainings with anti-bcl-2 protein 
antibody were performed on formalin-fixed, paraffin-embedded tissue sec-
tions. Biopsy specimens offollicular (centroblastic/centrocytic) lymphoma 
of the lymph nodes with the t{14;18) served as positive controls. Negative 
Immunohistochemical Evaluation Detailed immunophenotyping 
was performed in all cases on either frozen (44 cases) or routinely fixed, 
paraffin-embedded (64 cases) tissue sections, with a previously described 
three-step immunoperoxidase technique [19] using a panel of monoclonal 
Figure 1. Secondary cutaneous B-immunoblastic lymphoma. bcl-2 protein is present in immunoblasts in a perinuclear ring- and disc-like pattern (3-step 
immunoperoxidase, anti-bcl-2 antibody). 
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Figure 2. Secondary cutaneous B-lymphoblastic lymphoma with bcl-2-positive tumor cells (three-step immunoperoxidase, anti-bcl-2 antibody). 
controls were obtained by omitting the primary antibody or replacing it with 
normal human serum. 
Molecular Analyses Formalin-fixed, paraffin-embedded tissue from 25 
cases of B-cell cutaneous lymphoproliferative disorders (B-ceillymphoma, 
22' B-cell follicular pseudolymphoma-lymphocytoma cutis, three) were an-
al;zed for the t(14;18) using the highly sensitive PCR technique as briefly 
described previously [16]. A detailed list of the diagnoses of these 25 cases is 
shown in Table III. Three 15-ttm thick sections were cut from each paraffin 
block, and DNA was extracted as described [20]. Junctional sequences of 
rearranged chromosomes were amplified ill vitro by PCR using a primer 
annealing 5' to the 150-base pair (bp) cluster area within the bcl-2 major 
breakpoint region (lIIbr) on chromosome 18 in conjunction with a primer 
complementary to a universal JH sequence on chromosome 14 [21]. In addi-
tional reactions, a primer annealing to sequences of a minor cluster region 
(mer), whe~e breakage occurs in a. minority o~ cas~s [22], was used in con-
junction With the umversal JH pnmer. AmphficatlOn reactIOns were sepa-
rated by agarose gel electrophoresis, transferred to nylon membrane, and 
hybridized with a P32-labeled internal oligonucleotide hybridization probe 
for detection of specific amplification products. The hybridization probe 
used for detection of rearrangement within the IIIbr was an oligonucleotide 
annealing to the /IIbr region on chromosome 18 immediately 3' to the primer 
used for PCR (the "internal hybridization probe" as described by Crescenzi 
et af [21]). The probe used for detection of rearrangement within the Iller was 
an oligonucleotide annealing immediately internal to the 5' primer used for 
PCR. In previous studies, the: specificity of the amplification products had 
been further confirmed by direct DNA sequence analyses, which clearly 
showed the rearranged sequences. As positive control reactions, a segment of 
the p-actin gene was successfully amplified in all cases. Negative control 
reactions, using no DNA, were negative in all cases. 
Statistical Analysis For statistical analysis the X2 test was used to compare 
independent proportions. If any expected frequency was less than 2 or if 
more than 2 expected frequencies were less than 5, Fisher's exact test was 
performed [23]. 
RESULTS 
Inununohistochemical Analyses (Table I) In 16 of 63 cases of 
B-celilymphomas (5/42 primary, 11/21 secondary) bcl-2 protein 
was detected in the neoplastic cells. Identical results were obtained 
w hen more than one biopsy specimen was available for analysis. In 
positive cases, the vast majority of neoplastic cells showed perinu-
clear staining, usually associated with a paranuclear ring- and disc-
like pattern (Figs 1,2). 
Ge~minal centers of all B-cell follicular pseudolymphomas and 
all primary cutaneous T-cell lymphomas were negative. In 19 cases 
(B-ceillymphoma, 1~; T-cell lymphoma, four; B-cell pseudolym-
phoma, one) expression of the bcl-2 protein was found in small, 
reactive lymphocytes (Fig 3). 
Statistical Analysis (Table II) The proportion of bcl-2 protein-
positive cases was significantly higher in secondary (11/21) than in 
prim~ry ~utaneo~s B-celilymphomas (5/42,X2 = 12.1, P < 0.001). 
No Slgruficant difference was found for bcl-2 protein expression 
between low- and high-grade malignancy B-celllymphomas (x2 = 
1.0, P > 0.1). When the groups of primary and secondary cutaneous 
B-celllymphomas were separated into low- and high-grade malig-
nancy there was also no significant difference (primary cutaneous 
B-celllymphoma: low-grade 3/32, high-grade 2/10, Fisher's exact 
test: p = 0.34; secondary cutaneous B-cell lymphoma: low-grade 
6/10, high-grade 5/11, X2 = 0.4, P > 0.1). 
Molecular Analyses (Table III) In four of 11 cases of B-cell 
lymphomas positive for bcl-2 protein (one primary and three sec-
ondary), the t(14; 18) was detected by peR. All other cases analyzed 
on the molecular level, including five cases of B-cell lymphoma 
where expression of the bcl-2 protein was observed exclusively in 
reactive lymphocytes, were negative. 
DISCUSSION 
In this study, we demonstrated bcl-2 protein expression in five of 42 
cases (11.9%) of primary cutaneous B-ceillymphomas and in 11 of 
21 cases (52.4%) of secondary cutaneous B-celilymphomas. Com-
parison of proportions of bcl-2 - positive cases revealed a signifi-
cantly higher incidence in secondary than in primary cutaneous 
B-celllymphomas (x2 = 12.1 , P < 0.001). Detection of bcl-2 pro-
tein expression in a cutaneous lymphoproliferative lesion might 
warrant the extensive and accurate search for a possible nodal pri-
mary manifestation of the neoplasm. 
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Figure 3. Primary cutaneous centroblastic/centrocytic lymphoma. bcl-2 protein is detectable in reactive mantle zone and interfollicular lymphocytes but is 
absent in germinal centers (three-step immunoperoxidase, anti-bcl-2 antibody). 
In previous molecular studies using Southern blot analyses, no 
t(14;18) was detected in primary cutaneous B-cell lymphomas 
[14,15]. In our study, using the highly sensitive PCR technique, we 
detected the t( 14; 18) in one of 14 cases (7.1 %) of primary and three 
of eight cases (37.5%) of secondary cutaneous B-cell lymphoma. 
Similar differences between Southern blot and PCR results have 
also been observed in cases of intestinal lymphoma [24,25]. The low 
incidence of the t(14;18) in primary cutaneous B-cell lymphoma 
supports the hypothesis that different mechanisms may be involved 
in the genesis of nodal and cutaneous B-cell lymphomas. We did 
not find bcl-2 protein expression or molecular evidence for the 
t(14;18) in reactive cutaneous germinal centers (B-cell follicular 
pseudolymphomas). This confirms previous data in which benign 
follicular proliferations were negative [11,13]. 
PCR analysis of 11 cases with bcl-2 protein expression demon_ 
strated the t( 14; 18) in only four of them, indicating that in both 
primary and secondary cutaneous B-celilymphomas a correlation 
between bcl-2 protein expression and t(14;18) occurs in a small 
portion of the cases. This is consistent with observations by Pezzella 
et al [11,1~], .who reported several cases of nodal NHL expressing 
bcl-2 protem m. the abse~ce of the t(14;18). Alternative mechanisms 
of bcl-2 gene dlsregulatJon have been proposed to explain the pres-
Table ll. Comparison of Proportions of bcl-2 Protein Expression in Primary and Secondary Cutaneous B-Cell Lymphomas, 
and Cutaneous B-Cell Pseudo lymphomas 
Primary cutaneous B-celllymphoma 
Secondary cutaneous B-ceU lymphoma 
Primary cutaneous B-cell lymphoma (LGM)' 
Primary cutaneous B-cell lymphoma (HGM)b 
Secondary cutaneous B-celilymphoma (LGM) 
Secondary cutaneous B-celilymphoma (HGM) 
Primary and secondary cutaneous B-celilymphoma (LGM) 
Primary and secondary cutaneous B-cell lymphoma (HGM) 
Primary cutaneous B-celilymphoma 
Cutaneous B-cell pseudolymphoma 
• LGM, low-grade malignant. 
, HGM, high-grade malignant. 
+ 
5 
11 
3 
2 
6 
5 
9 
7 
5 
0 
bcl-2 Protein 
37 X2 = 12.1 
10 P < 0.001 
29 Fisher's exact test, 
8 P = 1.0 
4 X2 = 0.4 
6 p> 0.1 
33 X2 = 1 
14 p> 0.1 
37 Fisher's exact test, 
24 P = 0.34 
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Table III. Correlation of t(14;18) as Detected by PCR with the Expression of bcl-2 Protein as Detected by Immunohistochemistry in 
25 cases of Cutaneous Lymphoma and Pseudolymphoma 
Grades of 
Diagnosis Malignancy 
Primary cutancous B-cell lymphoma 
Lymphoplasmacytoid Low 
Ccntroblastic-centrocytic Low 
Centroblastic High 
Immunoblastic High 
Secondary cutaneous B-celilymphoma 
Centroblastic/centrocytic Low 
Centrocytic Low 
Ccntroblastic High 
Immunoblastic High 
Lymphoblastic High 
B-cell pseudo lymphoma 
Lymphocytoma cutis 
ence of high amounts of bcl-2 protein in cases without the t(14; 18) 
(i.e., trisomy of chromosome 18) [13]. However, the presence of 
detectable levels of bcl-2 protein within non-neoplastic Band T 
lymphocytes [11 ,13] suggests that expression of bcl-2 protein may 
occur also in the absence of oncogene activation. 
In both primary and secondary cutaneous B-celllymphomas the 
presence of bcf-2 protein expression and/or t( 14; 18) .did not corre-
late with a particular B-celllymphoma type. In particular, expres-
sion of bcl-2 protein was found in both low- and high-grade malig-
nancy cutaneous B-cell lymphomas without significant differences 
between the two groups (X2 = 1.0, r > 0.1). In the study by Pez-
zella et al [11], a high proportion 0 nodal T-cell lymphomas ex-
pressed the bcl-2 protein. We could not demonstrate bcl-2 protein 
expression in any of our 21 cases of pnmary cutaneous T-celi lym-
phoma. 
This study demonstrates that a small subset of primary cutaneous 
B-celilymphomas express the bcl-2 protein, and that a proportion of 
these cases might be characterized by the t(14;18). The differences 
in bcl-2 protein expression and incidence oft(14;18) between nodal 
and cutaneous lymphomas suggest that different mechanisms may 
be involved in the pathogenesis of these neoplasms. A possible path-
way for malignant proliferation of B lymphocytes within the skin 
implies amplification of the normal immune/response in the skin 
due to antigenic persistence and/or chronic antigenic stimulation 
[26]. 
We Ihallk Dr. D. Y. Masoll (OxJord) Jor killdly prollidirlg the allti-bcl-2 proteill 
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